We describe the isolation of a CCR5-specific antibody, ST6, from an antibody phage display library generated from an immune rabbit. ST6 was previously shown to efficiently prevent the surface expression of CCR5 when expressed intracellularly (Steinberger et al. (2000) Proc. Natl. Acad. Sci. U. S. A., 97, 805-10). Since ST6
INTRODUCTION
The chemokine receptor CCR5 is a principal HIV-1-coreceptor that plays a dominant role in disease transmission and in the early course of infection.
Individuals lacking a functional copy of CCR5 are highly protected against virus transmission (1) and several findings suggest that CCR5 expression levels are key in disease progression (2, 3) . The dispensable nature of CCR5 (4) makes this HIV-1 coreceptor an attractive therapeutic target. Here we report the isolation of a CCR5-specific antibody, ST6, from a phage displayed antibody fragment library generated from an immune rabbit. We have previously shown that ER-targeted expression of ST6 leads to functional deletion of the HIV-1 coreceptor CCR5 (5) . Gene therapeutic delivery of this intrabody into hematopoietic stem cells of infected individuals could be used to generate a cell pool that is protected from CCR5 dependent virus infection. To reduce (6, 7, 8) . We believe that a gene therapeutic approach that protects cells from infection has advantages over strategies that limit virus replication after infection of the target cell. Furthermore we suggest that specific functional deletion of CCR5 is less likely to have negative side effects compared to strategies based on intrakines (chemokines targeted to the ER) (9) . The chemokine ligands of CCR5 bind to other chemokine receptors e. g.
RANTES also binds to CCR1, CCR3, CCR9 (10) and the Duffy antigen receptor for chemokines. The consequences of inactivating a number of chemokine receptors cannot be predicted. 1 The abbreviations used are: CDR, complementarity determining region; ER, endoplasmic reticulum; Fd, heavy chain fragment; FR, framework region; HCDR, heavy chain complementarity determining region; HFR, heavy chain framework region; LCDR, light chain complementarity determining region; LFR, light chain framework region; mAb, monoclonal antibodies; PE, phycoerythrin; scFv, single chain antibody fragment; V L , light chain variable region; V H , heavy chain variable region. peptides fused to the C-terminus of the MBP were generated as described above and named after the putative epitope sequence. The sequence encoding the potential epitope was followed by a codon encoding glycine and a Table I and the library construction strategy is illustrated in 
EXPERIMENTAL PROCEDURES

Generation of Human V H Libraries with ST6-HCDR3:
Human V H genes were amplified from human bone marrow cDNA using FR1 and FR3-specific primers. A sense primer, HFR3, which contained the rabbit HCDR3 sequence flanked by human heavy chain FR3 and FR4 sequences was designed.
Using HFR3 in combination with the primer HSCG1234B 5' 
Generation of a Human V H Library with ST6-HCDR3 and -HCDR2
Sequences:
Using the PCR-crossover clone ST6-H2 that was selected from the first heavy chain-humanization libraries as a template, a V H fragment was amplified, using the sense . This V H library was combined with the four selected light chains to form a new scFv product (Fig. 1 B) . (Fig. 3B) . Several MBP fusion peptides were generated to determine the minimal epitope of ST6. ST6/34-IgG was also probed with the same fusion proteins to confirm that the epitopespecificity was retained in the humanization process (Fig. 3 C) . (Fig. 4 B) . Table II ). Association (k on ) and dissociation (k off ) rate constants were determined using surface plasmon resonance. CCR5-N-MBP was immobilized on the sensor chip. The dissociation constant (K d ) was calculated from k off /k on .
Transfection of 293T Cells Using Chemokine Receptor Encoding Plasmids and Intrabody Encoding Plasmids -
Modification
ST6/34-IgG and ST6-IgG Bind to Cells Expressing
A B ST6-H2
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